Skip to main content
. 2022 Mar 3;47(6):1263–1270. doi: 10.1038/s41386-022-01295-4

Table 1.

Baseline characteristics of youth with ASD randomly assigned to Mirtazapine or Placebo.

Mirtazapine (n = 20) Placebo (n = 10)
Age, Mean (SD) 10.9 (3.6) 11.3 (4.1)
Male, n (%) 17 (85%) 7 (70%)
White, n (%)1 17 (85%) 9 (90%)
Black or African American, n (%) 1 (5%) 1 (10%)
Asian, n (%) 1 (5%) 0 (0%)
Other Race, n (%) 1 (5%) 0 (0%)
Hispanic or Latino, n (%)2 2 (11%) 2 (20%)
DSM-IV Diagnosis, n (%)
Autistic Disorder 13 (65%) 8 (80%)
Asperger’s Disorder 3 (15%) 1 (10%)
PDD NOS 4 (20%) 1 (10%)
IQ, Mean (SD) 84.9 (22.5) 89.6 (23.6)
PPVT-4 Score, Mean (SD) 88.6 (27.5) 93.1 (22.2)
Vineland Adaptive Behavior II Composite Score, Mean (SD) 73.1 (12.3) 73.6 (12.5)
Clinical Global Impression–Severity subscale, n (%)3
4: Moderately Ill 7 (35%) 2 (20%)
5: Markedly Ill 13 (65%) 8 (80%)
Pediatric Anxiety Rating Scale, 5-Item Total, Mean (SD) 18.5 (2.9) 18.1 (2.8)
Screen for Childhood Anxiety Related Emotional Disorders, Mean (SD) 33.5 (13.9) 28.1 (8.8)
Child and Adolescent Symptom Inventory, Anxiety, Mean (SD) 26.0 (10.3) 19.7 (6.5)
Aberrant Behavior Checklist, Mean (SD)
I - Irritability 15.3 (8.2) 16.4 (9.9)
II - Lethargy/Social Withdrawal 14.9 (8.3) 6.2 (4.4)
III - Stereotypic Behavior 7.8 (5.7) 4.4 (4.5)
IV - Hyperactivity/Noncompliance 21.5 (10.7) 17.5 (13.2)
V - Inappropriate Speech 5.6 (3.8) 3.7 (2.9)
Children’s Sleep Habit Questionnaire, Mean (SD) 51.2 (9.5) 47.7 (6.8)
Developmental Disability-Child Global Assessment Scale, Mean (SD) 55.7 (6.1) 57.7 (6.1)

1Participants could select more than one race. No participants selected American Indian/Alaskan Native, or Native Hawaiian/Other Pacific Islander.

2Hispanic or Latino ethnicity was missing for two youth.

3No youth were rated 6 (Severely Ill) or 7 (Extremely Ill).

4ASD Autism spectrum disorder; PDD NOS Pervasive developmental disorder not otherwise specified; IQ intelligence quotient; PPVT-4 Peabody Picture Vocabulary Test, Fourth Edition.